SINGAPORE – April 21, 2026 – SG Austria/Austrianova (the SG Austria group comprising of Austrianova Singapore, Austrianova Thailand and Anovade UG) (the “Company”) is pleased to announce the appointment of C. Thomas Paschall, CEO and Founder of Checkmate Capital, to the Board of the SG Austria group as of April 4th, 2026. This comes after the previous successful closing of a preferred equity round led by Checkmate Capital Group in 2025.
Thomas brings many years of experience in biotech investments and advisory capability to the Company and had already been assisting the Company prior to his appointment to the Board. Checkmate Capital is U.S. West-coast based, but has a focus on Asia that overlaps well with that of SG Austria/Austrianova. He also has extensive Board experience, being a Board Member or Board Advisor to companies throughout the broader biotechnology, pharmaceutical, and medical technology industries. “We are thrilled to welcome Thomas on Board” said Walter H. Gunzburg, Chairman of SG Austria/Austrianova. “We have already benefited from Tom’s insight and experience, and we welcome the deepening and intensification of our relationship through his appointment to our Board. The financing round, which commenced in 2025, has enabled the Company to make critical capital expenditures and further pursue recent joint ventures and industry partnerships that have significantly contributed to increasing the Company’s value as it moves forward into 2026.”
About Austrianova
Austrianova (the SG Austria Group), is a biotech company with a global footprint and operations in Singapore, Thailand, and Germany. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications as well as re-balancing the microbiome due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid.
Austrianova now also offers Pep-in-a-Box encapsulation of enzymes, proteins, and supplements to protect them from stomach acid digestion, as well as GMP4Cells services that include competitively priced Master Cell Bank and Working Cell Bank production and other production services for cell therapy products (such as stem cell therapies and biologics produced from cells, e.g., recombinant proteins, exosomes, etc.).
Forward-Looking Statements
This release includes forward-looking statements regarding SGAustria (the Company) and its respective businesses. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks affecting the Company, economic factors, and the equity markets generally. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. This is not an offer or solicitation to buy or sell any securities.
SOURCE Austrianova
Financial Information Contact: pierre.faddoul@square-associates.com
Company and Technology Contact: salmons@sgaustria.com
For more information: http://www.austrianova.com
Media Contact
Company Name: Austrianova
Contact Person: Jay Lim
Email: Send Email
Country: Singapore
Website: http://www.austrianova.com
